PURE-01更新结果:新辅助帕博利珠单抗在肌层浸润性膀胱癌变异组织学中的初步活性
PURE-01是一项开放标签、单臂、2期研究,纳入T2-4aN0M0肌层浸润性膀胱癌患者,术前接受3周期200mg帕博利珠单抗后行根治性膀胱切除术。更新结果显示,总体病理完全缓解(pT0)率为37%(95%CI 28-46),pT≤1率为55%(95%CI 46-65);在 predominant 变异组织学患者中,鳞状细胞癌和淋巴上皮瘤样变异可见病理缓解,而其他变异组织学未见缓解。CPS和TMB与病理缓解相关,且不受组织学类型影响。
要点
- 新辅助帕博利珠单抗在肌层浸润性膀胱癌中pT0率为37%,pT≤1率为55%。
- predominant 变异组织学中,鳞状细胞癌和淋巴上皮瘤样变异可见病理缓解。
- CPS和TMB是预测病理缓解的关键生物标志物,与组织学亚型无关。
核心结论
- 更新PURE-01结果证实新辅助帕博利珠单抗在肌层浸润性膀胱癌中具有活性。
- 鳞状细胞癌和淋巴上皮瘤样变异患者可能适合新辅助免疫治疗试验。
- CPS和TMB是预测病理缓解的关键因素,不受组织学亚型影响。
研究设计与样本
- 开放标签、单臂、2期PURE-01研究(NCT02736266),纳入T2-4aN0M0肌层浸润性膀胱癌患者。
- 患者术前接受3周期200mg帕博利珠单抗,随后行根治性膀胱切除术。
- 2017年2月至2019年6月共纳入114例患者,其中34例(30%)存在变异组织学,19例(17%)为 predominant 变异组织学。
主要发现
- 总体pT0率为37%(95%CI 28-46),pT≤1率为55%(95%CI 46-65)。
- predominant 变异组织学中,鳞状细胞癌7例,6例(86%)降期至pT≤1,其中1例pT0;淋巴上皮瘤样变异3例中2例达pT0;其余9例 predominant 变异组织学均无缓解。
- 多变量分析显示,TMB和CPS与pT0及pT≤1缓解相关,且不受肿瘤组织学影响。
关键数值与推荐
- predominant 变异组织学定义为变异组织学占肿瘤标本>50%。
- PD-L1表达采用综合阳性评分(CPS;Dako 22C3抗体)评估。
- 全面基因组分析采用FoundationOne检测。
临床怎么用
- 新辅助帕博利珠单抗可作为肌层浸润性膀胱癌患者的治疗选择,尤其对鳞状细胞癌或淋巴上皮瘤样变异患者可能更有益。
- CPS和TMB可用于预测帕博利珠单抗的病理缓解,辅助患者选择。
局限性
- 本研究为单臂2期研究,样本量有限,尤其 predominant 变异组织学亚组例数较少。
- 变异组织学亚组的缓解结果为初步分析,需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with predominant variant histology (VH) of bladder tumors, defined as involving >50 % of the tumor specimens, are typically excluded from clinical trials, and for these patients, the efficacy of standard chemotherapy is limited. OBJECTIVE: To evaluate the activity of preoperative pembrolizumab in patients with muscle-invasive bladder carcinoma (MIBC) and VH, enrolled in PURE-01 study (NCT02736266). DESIGN, SETTING, AND PARTICIPANTS: In the open-label, single-arm, phase 2 PURE-01 study, three courses of 200 mg pembrolizumab preceding radical cystectomy (RC) were administered in T2-4aN0M0 MIBC patients. The amended study design included patients with predominant VH. INTERVENTION: Neoadjuvant pembrolizumab and RC. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Pathological complete response (pT0) in intention-to-treat population was the primary endpoint. Biomarker analyses included programmed cell-death ligand-1 (PD-L1) expression using the combined positive score (CPS; Dako 22C3 antibody) and comprehensive genomic profiling (FoundationOne assay). Multivariable logistic regression analyses (MVAs) evaluated the histological category (predominant VH vs nonpredominant VH vs pure urothelial carcinoma), tumor mutational burden (TMB) and CPS in association with the pathological response. RESULTS AND LIMITATIONS: From February 2017 to June 2019, 114 patients were enrolled; 34 (30%) of them presented with VH, including 19 (17%) with predominant VH. In total, the pT0 rate was 37% (95% confidence interval [CI]: 28-46) and the pT ≤ 1 rate was 55% (95% CI: 46-65). The majority of predominant VH patients presented with squamous-cell carcinoma (SCC; N = 7), and six of seven (86%) had downstaging to pT ≤ 1, with one pT0; two of three lymphoepithelioma-like (LEL) variants had a pT0 response. None of the remaining nine predominant VHs had a response. On MVA, TMB and CPS were associated with both the pT0 and the pT ≤ 1 response, regardless of tumor histology. CONCLUSIONS: The updated PURE-01 results confirm the activity of neoadjuvant pembrolizumab in MIBC. Patients with SCC and LEL features may be suitable for neoadjuvant immunotherapy trials. CPS and TMB are the key response predictors irrespective of the histological subtypes. PATIENT SUMMARY: In the PURE-01 study, we have preliminarily evaluated the activity of neoadjuvant pembrolizumab in patients with predominant variant histology (VH). Of these patients, those harboring squamous-cell carcinoma or a lymphoepithelioma-like variant feature had major, although preliminary, pathological responses compared with those with other predominant VHs. Expression of programmed cell-death ligand-1 and tumor mutational burden may predict the pathological response to pembrolizumab, and provide a rationale for selecting patients according to these features instead of the histological bladder cancer subtypes.
引用
- Necchi A, Raggi D, Gallina A, et al. Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant Histologies. Eur Urol. 2019. PMID: 31708296. doi:10.1016/j.eururo.2019.10.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。